[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"suicide\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:suicide":36},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,84,0,25,[9,50,86,108,154,178,198,229,254,283,309,336,361,385,397,422,449,479,502,531,557,583,609,629,652],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100053248","neural-derived-plasma-exosomal-micrornas-as-promising-novel-biomarkers-for-suicidality-and-treatment-outcome-in-adolescents-100053248",false,"NCT05437588","Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents","Inclusion Criteria:\n\nAll participants:\n\n1. Physically healthy\n2. willing and able to provide informed consent (if under 18 also parent or guardian consent)\n\nMDD participants:\n\n1. A definite diagnosis of DSM-5\n2. a Children's Depression Rating Scale-Revised (CDRS-R) score \\>=30. Suicidal ideation participants: Columbia Suicide Severity Rating Scale (C-SSRS) score \\>=4 rated over the last two weeks.\n\nSuicide attempt group:\n\n1\\. Participants will have had an attempt in the previous two weeks that is serious enough to require medical attention and shows evidence of at least a medium level of intent on the Suicide Intent Scale.\n\nNon-psychiatric controls:\n\n1\\. No history of any major mental illness (excluding specific phobia) or substance use disorder.\n\nExclusion Criteria:\n\n* Exclusion criteria:\n\n  1. Pregnancy or lactation\n  2. post-partum state (being within 2 months of delivery or miscarriage);\n  3. homicide risk as determined by clinical interview\n  4. any of the following DSM-V diagnoses or categories: a) a lifetime history of psychotic disorder; b) alcohol or drug use disorder (except nicotine\u002Fcaffeine) within the last month; the use of any hallucinogen (except cannabis), including phencyclidine in the last month; c) bipolar disorder; d) pervasive developmental disorder; e) cognitive disorder; f) DSM-5 paranoid, schizoid, or schizotypal personality disorders (PDs) (participants with other PDs will be allowed as long as MDD criteria are met); g) anorexia nervosa.\n  5. recent myocardial infarction or unstable angina, active neoplasm in the past 6 months, immunosuppressive or corticosteroid therapy within the last month, chemotherapy, and head injury or loss of consciousness in the past 6 months\n  6. use of hallucinogens (except for cannabis), methamphetamine, or cocaine in the last 2 weeks.",true,"ALL","10 Years","24 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study is dedicated to help identify biomarkers for depression and suicide. The purpose of the study is to better understand these links to improve medical and psychiatric care in the future. This research is also to test the effects of standard treatment of depression on improvement in depressive and suicidal behavior and on biomarkers (e.g. miRNA) for these disorders.",[28,29,30,31,32,33,34,35,36],"Major Depressive Disorder","Suicidal Ideas","Suicide, Attempted","MDD","Depression","Depression, Teen","Depression and Suicide","Depression in Adolescence","Suicide","RECRUITING","2026-07-10",{"date":40,"type":41},"2026-07-13","ACTUAL",{"date":43,"type":41},"2022-10-01",{"date":45,"type":22},"2027-06-30",{"name":47,"class":48},"University of Alabama at Birmingham","OTHER",2,{"id":51,"slug":52,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":23,"phases":61,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100054040","phase-2-inhaled-dmt-for-major-depressive-disorder-100054040","NCT07562191","Inhaled DMT for Major Depressive Disorder","Randomized, Double-Blind, Placebo-Controlled Phase IIb Trial of Inhaled N,N-Dimethyltryptamine (DMT) for Major Depressive Disorder","DMT-MDD","Inclusion Criteria:\n\n* 18 years or older, capable of making decisions, and able to provide informed consent.\n* Major Depressive Disorder (MDD) according to DSM-5 criteria\n* Current depressive episode of moderate to severe intensity\n* Episode duration of at least two weeks\n* Baseline MADRS score ≥ 20\n* No treatment changes (including antidepressants) in the 4 weeks prior to the study\n* Abstain from psychedelics ≥14 days before dosing (D0)\n\nExclusion criteria:\n\n* Major cardiac, hepatic, or renal disease; unstable cardiovascular conditions\n* Uncontrolled hypertension, QTc prolongation, arrhythmias, or valvular disease COPD or asthma\n* Severe obesity, uncontrolled diabetes, coagulopathy, thyroid disease, or glaucoma\n* Neurological risk (e.g., aneurysm, ↑ICP, epilepsy\u002Fseizures, severe disorders)\n* MAO deficiency or history of serotonin syndrome\n* Pregnant, breastfeeding, positive test, or no effective contraception\n* Secondary depression\n* Cluster B personality disorders (incl. borderline with ≥2 suicidal behaviors in past 12 months) or poor therapeutic rapport\n* Psychotic disorders, MDD with psychotic features, or first-degree family history of psychosis\u002Fbipolar disorder\n* Mania\u002Fhypomania\n* OCD, dissociative disorders, active PTSD, or decompensated eating disorders\n* Moderate-severe use disorder (past 6 months; except nicotine\u002Fcaffeine)\n* Lifetime ketamine, PCP, psychedelics, or MDMA use disorder\n* Current use of MAO inhibitors, unless discontinued at least 14 days prior to dosing\n* Psychedelic trial participation in past 12 months\n* Cognitive impairment affecting valid assessment","18 Years",{"count":60,"type":22},140,[62],"PHASE2","This Phase 2b, randomized, double-blind, active-controlled clinical trial will evaluate the efficacy and safety of inhaled N,N-dimethyltryptamine (DMT) in adults with Major Depressive Disorder (MDD).\n\nThe study will test whether inhaled DMT can rapidly reduce depressive symptoms and suicide risk compared with a low-dose active comparator. A total of 140 participants will be randomized 1:1 to receive either 15 mg followed 1 hour later by 60 mg of inhaled DMT, or 1 mg followed 1 hour later by 4 mg of inhaled DMT.\n\nParticipants who do not achieve remission at Day 7 will enter an open-label extension and receive a high-dose DMT session on Day 14 (±3 days). All participants will be followed for up to 12 months to evaluate the durability of response, safety, functioning, and quality of life.",[31,65,66,67,36],"Major Depressive Disorder (MDD)","Major Depression","Suicidal Ideation",[69,70,71,72,73,74,75,76],"DMT","major depressive disorder","N,N-dimethyltryptamine","psychedelic therapy","inhaled DMT","vaporized DMT","suicidality","non invasive","2026-07-09",{"date":40,"type":41},{"date":80,"type":22},"2026-08-01",{"date":82,"type":22},"2027-08-01",{"name":84,"class":48},"Universidade Federal do Rio Grande do Norte",5,{"id":87,"slug":88,"hasResults":12,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":4,"eligibilityCriteria":92,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100480895","scaling-up-e-connect-in-juvenile-probation-settings-100480895","NCT05541926","Scaling up e-Connect in Juvenile Probation Settings","Scaling up eConnect in Juvenile Probation Settings: a Hybrid Implementation Effectiveness Trial of a Digital Suicide Risk\u002FBehavior Identification and linkage-to Treatment System","Sample: County Probation Staff\n\nInclusion Criteria:\n\n* All probation agency leadership and officers employed by the partnering sites who are (a) at least 18 years of age and (b) conversant in English in participating study counties are eligible\n\nExclusion Criteria:\n\n* There are no exclusionary criteria and no special classes of participants.\n\nSample: County Treatment Staff\n\nInclusion Criteria:\n\n* All treatment staff (agency directors, supervisors and clinical line staff) employed by participating treatment agencies who are at least 18 years of age and conversant in English in participating study counties will be asked to participate\n\nExclusion Criteria:\n\n* There are no exclusionary criteria and no special classes of participants.\n\nSample: Local Facilitators\n\nInclusion Criteria:\n\n* All county\u002Flocal Justice Diversion Alternatives Initiative (JDAI) representatives that work with partnering sites who (a) are at least 18 years of age and (b) conversant in English in participating study counties are eligible\n\nExclusion Criteria:\n\n* There are no exclusionary criteria and no special classes of participants.\n\nSample: Probation Youth\n\nInclusion Criteria:\n\n* All youth who are on probation who are (a) 10-18 years of age and (b) conversant in English in participating study counties are eligible;\n\nExclusion Criteria:\n\n* There are no exclusionary criteria and no special classes of participants.",{"count":94,"type":22},3629,[25],"We propose to conduct research on strategies that support the successful scale-up of an evidence-based, suicidal risk and behavior identification and cross-system linkage programs for justice-involved youth (e-Connect), and to rigorously evaluate the implementation activities and associated costs that support that scale-up of e-Connect within 9 Indiana counties. Guided by the GPM and EPIS frameworks, this 4-year study will comprise 3 project phases: (1) Scale-Up Strategy Efforts, focused on preparing for scale-up; (2) e-Connect-scaleup implementation (2a Exploration and Preparation and 2b Implementation and Sustainment); and (3) Scale-Up Effectiveness Trial\u002FOutcome Evaluation. The current project draws on lessons learned from the e-Connect efficacy trial in NYS and research team leadership will serve as External Facilitators to support 9 Local Facilitators to ensure the successful transfer of knowledge, skill and expertise in delivering e-Connect in a new JJ system and geographic context, utilizing implementation strategies to support the more widespread, sustained and rigorous adoption of e-Connect. The study will include a learning community created by External Facilitators for Local Facilitators to provide support, to exchange strategies to handle implementation issues, to develop competencies in facilitation, and to guide implementation throughout the program. The learning community will help Local Facilitators navigate through the implementation stages of the study.",[36],"2026-06-28",{"date":100,"type":41},"2026-06-30",{"date":102,"type":41},"2023-05-02",{"date":104,"type":22},"2028-08-31",{"name":106,"class":48},"New York State Psychiatric Institute",1,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":112,"acronym":4,"eligibilityCriteria":113,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":114,"enrollmentInfo":115,"targetDuration":4,"studyType":117,"phases":4,"briefSummary":118,"conditions":119,"keywords":139,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":107},"100551600","natural-history-of-depression-bipolar-disorder-and-suicide-risk-100551600","NCT06462196","Natural History of Depression, Bipolar Disorder and Suicide Risk","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n* Signed consent for Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers\n* Age 18 years or older\n* Able to provide informed consent\n* Able to read and write English\n\nEXCLUSION CRITERIA:\n\n* Unstable medical conditions in the opinion of the investigator that would preclude participation in outpatient or inpatient treatment.\n* Pregnancy\n* Participation in the Protocol 01-M-0254: The Evaluation of Patients with Mood and Anxiety Disorders and Healthy Volunteers, as a healthy volunteer.\n* Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to consent and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to enrolling in the study. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician.","120 Years",{"count":116,"type":22},500,"OBSERVATIONAL","Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide.\n\nPeople 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254.\n\nThis study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time.\n\nParticipants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation.",[120,36,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,28,138],"Behavioral Symptoms","Self-Injurious Behavior","Sensory System Agents","Analgesics","Peripheral Nervous System Agents","Physiological Effects of Drugs","Anesthetics, Dissociative","Anesthetics, General","Anesthetics","Central Nervous System Depressants","Excitatory Amino Acid Antagonists","Excitatory Amino Acid Agents","Neurotransmitter Agents","Molecular Mechanisms of Pharmacological Action","Ketamine","Depression, Unipolar","Depressive Symptoms","Treatment Resistant Depression","Depression, Bipolar",[140,36,28,141,142,143,137],"Neurobiology","Bipolar Disorder","Biomarkers","Suicide Risk","2026-06-26",{"date":146,"type":41},"2026-06-29",{"date":148,"type":41},"2024-09-09",{"date":150,"type":22},"2030-06-01",{"name":152,"class":153},"National Institute of Mental Health (NIMH)","NIH",{"id":155,"slug":156,"hasResults":12,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":19,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":107},"100645259","peer-delivered-youth-suicide-prevention-in-nepal-100645259","NCT07680179","Peer Delivered Youth Suicide Prevention in Nepal","Innovations for Peer-delivered and Family-engaged Brief Interventions for Youth Suicide in Nepal: A Pilot Hybrid Type 2 Implementation Study","Inclusion Criteria:\n\nPeer Volunteers\n\n* Age ≥18 years\n* No current untreated mental disorder or suicide risk, as assessed and confirmed by a Nepali mental health specialist (MD or PhD)\n* Meets hiring and eligibility criteria of the local implementing partner NGO\n* Fluent in spoken Nepali\n\nTrial Youth Patient Participants\n\n* Age 12-24 years\n* Resident of the study site\n* Screens positive to the Nepali Ask Suicide Screening Questions or a lifetime history of a suicide attempt\n* Ability to provide informed consent or assent\n* For participants under 18 years of age, written informed consent from a legal guardian\n* Fluent in Nepali\n\nFamily Members (intervention group only)\n\n* Family member (defined as any individual that is a parent, grandparent, aunt\u002Funcle, or cousin as well as significant others) selected by the youth participants enrolled in the study\n* Resident of the study site\n* Over 18 years of age\n* Ability to provide informed consent or assent\n* Fluent in Nepali\n\nExclusion Criteria:\n\nPeer Volunteers\n\n* Plans to leave the peer volunteer role within the next 6 months\n* Unable to provide voluntary informed consent for any reason\n\nTrial Youth Patient Participants\n\n* Requires immediate psychiatric hospitalization at the time of assessment\n* Unable to provide informed consent or assent due to impaired decision-making capacity\n* Participants under 18 years of age without written informed consent from a legal guardian\n* Planning to leave the study area in the next 6 months\n\nFamily Members\n\n* Requires immediate psychiatric hospitalization at the time of assessment\n* Unable to provide informed consent or assent due to impaired decision-making capacity\n* Planning to leave the study area in the next 6 months","12 Years",{"count":163,"type":22},160,[25],"South Asia has the highest suicide rate in the world with important risk profile differences from high-income settings. Investigators will conduct formative research to co-design a package of brief interventions and implementation strategies to prevent youth-suicide and then test the package in a pilot feasibility hybrid type 2 cluster randomized controlled trial in Nepal. Potential health impacts may be substantial as results can be applied not only in similar South Asian primary healthcare contexts, but also in low-resource settings in the US and abroad, where the suicide burden remains high.\n\nUsing experience-based co-design and equity-focused implementation frameworks, this study will assess the feasibility and acceptability of a Youth-focused, Peer-delivered, Family-engaged Suicide Prevention Package (YPF-SuPP) integrated within existing mhGAP services in Nepal's decentralized primary healthcare system. This pilot trial will generate preliminary data to inform the design of a future fully powered effectiveness trial and potential scale-up of youth suicide prevention strategies.",[36,167],"Suicide Prevention","NOT_YET_RECRUITING","2026-06-25",{"date":171,"type":41},"2026-07-02",{"date":173,"type":22},"2026-06",{"date":175,"type":22},"2028-06",{"name":177,"class":48},"Yale University",{"id":179,"slug":180,"hasResults":12,"nctId":181,"briefTitle":182,"officialTitle":182,"acronym":4,"eligibilityCriteria":183,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":23,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":107},"100490823","effectiveness-and-implementation-of-a-clinician-decision-support-system-to-prevent-suicidal-behaviors-100490823","NCT05671133","Effectiveness and Implementation of a Clinician Decision Support System to Prevent Suicidal Behaviors","Inclusion Criteria:\n\n* Adult status (≥18 years-old);\n* Willing to provide an email address;\n* Presentation at the APS\n\nExclusion Criteria:\n\n* Inability to understand the study procedures and provide informed consent such as those with gross cognitive impairment (including florid psychosis), intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior\n* Decisions about inclusion\u002Fexclusion criteria will be made by the emergency department providers on duty at the time. These broad inclusion criteria maximize the clinical applicability of obtained results while the exclusion criteria ensure the ethical principle of respect for persons.",{"count":185,"type":22},4000,[25],"The primary aim of this project are to evaluate a comprehensive, practice-ready, and deployment-focused strategy for improving the prediction and prevention of suicide attempts among a sample of 4,000 patients presenting to an ED with a psychiatric concern. The first aim is to evaluate the effects of providing information about risk of patient suicidal behavior to ED clinicians. The investigators hypothesize that patients randomly assigned to have their clinician receive their risk score will have a lower rate of suicide attempts during 6-month follow-up and that this effect will be mediated by changes in clinician decision-making.",[36,30],"2026-06-16",{"date":191,"type":41},"2026-06-22",{"date":193,"type":41},"2025-02-25",{"date":195,"type":22},"2028-09-28",{"name":197,"class":48},"Massachusetts General Hospital",{"id":199,"slug":200,"hasResults":12,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":216,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":222,"lastUpdatePostDateStruct":223,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":107},"100555424","phase-2-investigation-of-the-antidepressant-effects-of-2r6r-hnk-an-enhancer-of-synaptic-glutamate-release-in-treatment-resistant-depression-100555424","NCT06511908","Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","An Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression","* INCLUSION CRITERIA:\n\nIn order to be eligible to participate in this study, an individual must meet all of the following criteria:\n\n1. Ability of participant to understand and willingness to sign a written informed consent document. To verify this, participants must score \\>= 80% on the consent quiz.\n2. Stated willingness to comply with all study procedures and availability for the duration of the study.\n3. 18 to 70 years of age.\n4. All participants must have undergone a screening assessment under protocol 01-M-0254.\n5. Participants must fulfill DSM-IV or DSM-5 criteria for MDD, single episode or recurrent without psychotic features, based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P). Participants must be experiencing a current major depressive episode lasting at least two weeks.\n6. Participants must have an initial score of \\>= 20 on the MADRS and a YMRS score of \\\u003C12 within one week of study entry and upon entry into Phase II.\n7. Ability to take intravenous medication and be willing to adhere to the (2R,6R)-HNK regimen.\n8. Participants must have a current or past history of lack of response to at least one adequate antidepressant trial (may be from the same chemical class), with at least one in the current major depressive episode, operationally defined using the modified Antidepressant Treatment History Form (ATHF); non-response to an adequate trial of ECT or TMS would count as an adequate antidepressant trial.\n9. For individuals of reproductive potential: use of highly effective contraception starting at the time of enrollment and agreement to use such a method during study participation and for an additional four weeks after the end of Study Phase II.\n10. For males of reproductive potential: use of condoms or other methods from the time of enrollment to ensure effective contraception with partner, and for an additional 90 days after the end of Phase II.\n11. Agreement to adhere to Lifestyle Considerations throughout study duration.\n12. Medically healthy, or with stable, treated, chronic medical conditions (provided any medications are not excluded)\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Current use of disallowed concomitant medications or transcranial magnetic stimulation (TMS) two weeks prior to the start of Phase II.\n2. Treatment with a reversible monoamine oxidase inhibitor (MAOI) four weeks prior to the start of Phase II.\n3. Treatment with fluoxetine, aripiprazole, or brexpiprazole five weeks prior to the start of Phase II.\n4. Treatment with clozapine or electroconvulsive therapy (ECT) four weeks prior to the start of Phase II.\n5. Ongoing treatment with moderate or strong CYP3A4\u002F5 inhibitors or inducers\n6. Lifetime history of deep brain stimulation.\n7. Previous antidepressant non-response to ketamine or esketamine (full course).\n8. No structured psychotherapy will be permitted during the total duration of the study. Participants unable or unwilling to stop psychotherapy will be unable to participate in the study.\n9. Pregnancy or lactation.\n10. Current psychotic features or a diagnosis of schizophrenia or any other psychotic disorder as defined in the DSM-IV or DSM-5.\n11. Participants with a history of DSM-IV substance or alcohol abuse or dependence, or DSM-5 substance use disorder (except for caffeine, nicotine, or cannabis), or moderate to severe alcohol use disorder, within the preceding three months. In addition, participants who are currently using drugs (except for caffeine, nicotine, or cannabis) must not have used illicit substances or known drugs of abuse in the two weeks prior to screen and must have a negative drug urine test (except for prescribed benzodiazepines or stimulants) prior to starting Phase II. Cannabis use is exclusionary if the use is daily, or if participants are unable to abstain during the study, or if function of daily life is impaired by use as determined by a clinician. Due to the interactions between cannabis and SSRIs, frequent cannabis use during previous antidepressant treatment will result in that treatment being considered a failed trial for eligibility purposes.\n12. Participants with a DSM-IV or DSM-5 Axis II diagnosis of borderline or antisocial personality disorder.\n13. Participants with a history of head injury that resulted in loss of consciousness exceeding five minutes (for the imaging component of the study).\n14. No serious, unstable medical illnesses including but not limited to the following body systems and organs or those that in the judgment of the Principal Investigator pose a risk to the participant's ability to safely participate in the study: Hepatic diseases (e.g. active viral hepatitis infection or cirrhosis of the liver, any liver disease with Child-Pugh score \\>=5), cardiovascular disease (including ischemic heart disease, coronary artery disease, congestive heart failure, poorly controlled hypertension due to risk of further blood pressure elevation and increase in demand on cardiac function from study drug), renal\u002Furologic (e.g chronic kidney disease or acute kidney injury, history of bladder dysfunction due to theoretical risk of ketamine-induced cystitis, moderate to severe renal impairment of any etiology), endocrinologic (including uncontrolled diabetes due to association with progressive abnormality of the microvasculature and nervous system), or neurologic disease (e.g. elevated intraocular pressure or history of or presence of diseases that are associated with elevated intracranial pressure).\n15. Participants with unstable clinical hyperthyroidism or hypothyroidism.\n16. Participants with one or more seizures without a clear and resolved etiology.\n17. Clinically significant abnormal laboratory tests specifically defined by:\n\n    * Alkaline phosphatase (Alk Phos) \\> 150 U\u002FL\n    * Alanine aminotransferase (ALT) \\> 55 U\u002FL\n    * Aspartate aminotransferase (AST) \\> 34 U\u002FL\n    * Total bilirubin (TB) \\> 1.2 mg\u002FdL\n    * Direct bilirubin (DB) \\> 0.5 mg\u002FdL\n    * 25-hydroxyvitamin D \\\u003C 20 ng\u002FmL\n    * Folate \\\u003C 2ng\u002FmL\n    * Vitamin B12 \\\u003C 200 pg\u002FmL\n18. Moderate to severe renal impairment with body surface area corrected eGFR \\\u003C60mL\u002Fmin.\n19. Participants who, in the Principal Investigator's judgment, pose a current serious suicidal or homicidal risk.\n20. Positive HIV test.\n21. Contraindications to MRS (metal in body, claustrophobia, etc. for imaging)\n22. Participants with COVID-19 or suspected COVID-19\n23. Inability to read and understand English. Non- English speakers will not be eligible as most of the required monitoring and rating instruments are not validated in languages other than English.","70 Years",{"count":207,"type":22},50,[62],"Background:\n\nMajor depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective. Researchers want to know if a faster-acting drug, (2R,6R)-hydroxynorketamine (HNK), can better treat the symptoms of MDD.\n\nObjective:\n\nTo test a study drug (HNK) in people with MDD.\n\nEligibility:\n\nPeople aged 18 to 70 years with MDD. They must have had a screening assessment under protocol 01-M-0254.\n\nDesign:\n\nParticipants will be tapered off their current MDD drugs over 2 to 5 weeks. They will stay off of the drugs for up to 2 weeks prior to starting the study medication and procedures. They will have a physical exam with blood tests. They will have tests of their heart function, mood, and thinking. They will answer questions about their symptoms. They may choose to have imaging scans and scans of their brain activity.\n\nHNK is given through a tube attached to a needle inserted into a vein. Participants will receive infusions on this schedule:\n\nThey will receive 4 infusions over 2 weeks. They will stay in the clinical center overnight after each infusion or for the duration of the study.\n\nThey will receive no drugs for 2 to 3 weeks.\n\nThey will have 4 more infusions over 2 weeks, with overnight stays after each or for the duration of the study.\n\nOne set of 4 infusions will be the HNK. The other set of 4 infusions will be a placebo. A placebo looks just like the real drug but contains no medicine. Participants will not know when they are getting the HNK or placebo.\n\n...",[36,211,134,133,132,131,125,212,213,32,214,215,120],"Depressive Disorder, Treatment-Resistant","Depressive Disorder, Major","Depressive Disorder","Mental Disorders","Mood Disorders",[28,134,142,217,218,219,140,220,221],"Neuropharmacology","Magnetic Resonance Imaging","Magnetoencephalography","Glutamate","Hydroxynorketamine","2026-06-13",{"date":189,"type":41},{"date":225,"type":41},"2024-11-06",{"date":227,"type":22},"2027-07-01",{"name":152,"class":153},{"id":230,"slug":231,"hasResults":12,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":12,"sex":17,"minAge":236,"maxAge":58,"enrollmentInfo":237,"targetDuration":4,"studyType":23,"phases":239,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":250,"leadSponsor":252,"locationsCount":107},"100542980","a-pilot-evaluation-of-a-digital-peer-support-intervention-for-suicidal-adolescents-100542980","NCT06349915","A Pilot Evaluation of a Digital Peer Support Intervention for Suicidal Adolescents","SWEEP","Inclusion Criteria:\n\n* past-month history of suicidal thoughts\n* past-month history of Major depressive disorder\n* possession of apple or android smartphone with data plan\n\nExclusion Criteria:\n\n* inability to read\u002Fwrite in English\n* Active mania\n* Active psychosis\n* Autism spectrum disorder","14 Years",{"count":238,"type":22},46,[25],"Suicide risk has increased among youth in underserved communities, where access to mental healthcare is limited. To address this need, the investigator team plans to evaluate the preliminary efficacy of a brief, low-cost, culturally responsive digital intervention for ethnically diverse youth at risk for suicide in The Bronx, New York. In collaboration with community stakeholders, suicide recovery narratives, featuring adolescents' experiences related to recovery from suicidal thoughts will be developed. A smartphone ecological momentary assessment (EMA) app will be used to evaluate whether a curriculum of these narratives provides anti-suicidal benefits to at-risk adolescents.",[36],[243,244,245],"digital intervention","community participation","ecological momentary assessment","2026-06-09",{"date":248,"type":41},"2026-06-11",{"date":173,"type":22},{"date":251,"type":22},"2027-12",{"name":253,"class":48},"Albert Einstein College of Medicine",{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":263,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":107},"100624065","evaluation-of-a-telehealth-case-management-intervention-to-prevent-suicide-among-soldiers-discharged-from-psychiatric-hospitalization-100624065","NCT07404787","Evaluation of a Telehealth Case Management Intervention to Prevent Suicide Among Soldiers Discharged From Psychiatric Hospitalization","SAFEGUARD Phase 2 Pathfinding Study","Inclusion Criteria:\n\n* Active duty Regular Army soldiers recently discharged from inpatient psychiatric care at a military treatment facility in the US\n* Access to telephone and computer (including smartphone)\n\nExclusion Criteria:\n\n* Impaired ability to provide informed consent\n* Terminal illness\n* Failure to complete baseline survey within 30 days of discharge\n* Positive screen for post-discharge suicide-related behaviors",{"count":262,"type":22},1500,[25],"This study evaluates the effectiveness of Pathfinding, a 6-month, remotely-delivered case management intervention designed to decrease suicidal behavior among active-duty Regular Army soldiers recently discharged from inpatient psychiatric treatment. Soldiers discharged from military treatment facilities across the U.S. will be identified and recruited to participate. Those who consent will be randomly assigned to receive either Treatment As Usual (TAU), which is the Army's standard post-discharge care, or TAU plus Pathfinding. Participants will complete a baseline assessment and follow-up assessments 6 months and 12 months later. The 6- and 12-month follow-up periods will also include examination of participants' electronic healthcare data and Army administrative data. The overall goals of the study are: (1) to evaluate whether Pathfinding decreases suicidal behaviors among soldiers transitioning from psychiatric hospitalization back to the community; and (2) to determine which discharged soldiers are most likely to benefit from the Pathfinding intervention versus TAU alone.",[36,266],"Suicide Attempt",[268,269,270,271,272,273],"suicide","suicide attempt","hospital discharge","military","intervention","case management","2026-06-08",{"date":248,"type":41},{"date":277,"type":41},"2026-02-24",{"date":279,"type":22},"2029-08-31",{"name":281,"class":282},"Uniformed Services University of the Health Sciences","FED",{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":23,"phases":294,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":308},"100575270","suicide-assessment-and-feasible-evidence-based-treatments-for-youth-living-with-hiv-in-lilongwe-100575270","NCT06770101","Suicide Assessment and Feasible Evidence-based Treatments for Youth Living With HIV in Lilongwe","Suicide Assessment and Feasible Evidence-based Treatments for Youth Living With HIV in Lilongwe: SAFETY Planning Pilot Trial","Inclusion Criteria:\n\n* Age 13-19\n* Diagnosed with HIV\n* Report current or historical suicidal ideation and behaviors (SIBs) on question 9 of the Patient Health Questionnaire modified for adolescents (PHQ-9-A) and the Ask Suicide-Screening questionnaire (ASQ)\n* Living in the clinic's catchment area with intention to remain for more than 1 year\n* Willing to provide consent (age 18+ or 16-17 years old and married and thereby considered emancipated minors per Malawi law) or assent with parental consent (age 13-17).\n\nExclusion Criteria:\n\n* Refuse to participate\n* Refuse to be audio-taped for in-depth interviews","13 Years","19 Years",{"count":293,"type":22},60,[25],"The overall aim of this study is to determine the feasibility, fidelity, acceptability, and preliminary effectiveness of the Friendship Bench +Safety Planning intervention in reducing suicidal ideation and behaviors (SIBs) and improving HIV engagement amongst adolescents living with HIV (ALWH) when compared to augmented usual care.",[297,36],"HIV",[297,36,67],"2026-06-04",{"date":301,"type":41},"2026-06-05",{"date":303,"type":41},"2025-07-01",{"date":305,"type":22},"2026-09",{"name":307,"class":48},"University of Pennsylvania",4,{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":58,"enrollmentInfo":316,"targetDuration":4,"studyType":23,"phases":318,"briefSummary":319,"conditions":320,"keywords":323,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":49},"100590134","transdiagnostic-sleep-and-circadian-intervention--bright-light-in-adolescents-with-elevated-depression-trans-cbl-100590134","NCT06963463","Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression (TranS-C+BL)","Transdiagnostic Sleep and Circadian Intervention + Bright Light in Adolescents With Elevated Depression","Inclusion Criteria:\n\n* Adolescents (12-18)\n* Current moderate to severe depression as measured by the PHQ-9M with a total score of greater than or equal to 11\n* Current clinically significant sleep disturbance measured by the PHQ-9-M sleep item greater than or equal to 2.\n* English language fluency and literacy sufficient to engage in study protocol.\n\nExclusion Criteria:\n\n* Evidence of obstructive sleep apnea,\n* Evidence of restless legs syndrome\n* Evidence of psychosis\n* Evidence of bipolar disorder\n* Evidence of a developmental disability precluding comprehension of study procedures per electronic health record and eligibility screening.",{"count":317,"type":22},90,[25],"The goal of this clinical trial is to adapt a sleep intervention for individuals representative of all demographic groups, including those who are at the highest risk for suicidal behavior. Sleep difficulties are a promising target for youth with suicidal thoughts and behavior to focus on as a prevention measure. We aim to increase intervention acceptability and impact by adapting it for the adolescent populations at highest risk for suicidal thoughts and behavior. The research project will compare Transdiagnostic Sleep and Circadian Intervention (TranS-C), an evidence based, modularized intervention that targets a range of sleep difficulties to a treatment as usual or control condition including providing weekly sleep feedback reports from data entered into a daily sleep diary and from wearing a sleep sensing, actigraphy watch. Participants in both conditions (TranS-C vs. Sleep Feedback) will wear an actigraphy sleep watch that monitors sleep, and complete daily sleep diaries via smartphone or email. Participants in the TranS-C condition will also wear bright light (BL) and blue blocking glasses each day as well as attend weekly or biweekly sessions with a Sleep Therapist. The sleep therapist will review sleep feedback during sessions.",[321,322,32,36],"Sleep Disturbance","Sleep",[324,325,326,327],"Sleep Disturbances","Objective Sleep","Subjective Sleep Difficulties","Minority Youth","2026-06-02",{"date":299,"type":41},{"date":331,"type":41},"2025-05-06",{"date":333,"type":22},"2027-07-31",{"name":335,"class":48},"University of Pittsburgh",{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":290,"maxAge":343,"enrollmentInfo":344,"targetDuration":4,"studyType":23,"phases":346,"briefSummary":347,"conditions":348,"keywords":349,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":107},"100622445","nudging-parental-actions-for-youth-suicide-prevention-100622445","NCT07383714","Nudging Parental Actions for Youth Suicide Prevention","Nudging Parental Action With A Randomized Controlled Trial of Text Messaging Intervention for Suicide Prevention","Inclusion Criteria:\n\n* Guardian must be able and willing to provide informed consent, and the participant must be able and willing to provide assent.\n* Parent and adolescent willingness and ability to participate in study procedures and complete assessments at baseline, 6 weeks, and 12 weeks.\n* Presentation to the ED for a suicide-related emergency, defined as suicidal ideation within the last 2 weeks or a suicide attempt within the past month.\n* Adolescents aged 12-17 years during the consent.\n* Access to a mobile phone with text messaging capability for the parent\u002Flegal guardian.\n* Ability to communicate in English.\n\nExclusion Criteria:\n\n* Absence of a legal guardian capable of providing consent.\n* Parents\u002Flegal guardians without access to a mobile phone with texting capability.\n* Inability to communicate in English.\n* Adolescents in state custody or under legal restrictions that prevent study participation.\n* Adolescents involved in the justice system in a manner that would interfere with study participation.\n* Adolescents with autism spectrum disorder or intellectual development disorder needing substantial or very substantial support","17 Years",{"count":345,"type":22},129,[25],"The goal of the study is to determine effectiveness of a behaviorally informed text messaging intervention to help parents increase safety practices and reduce their teens' access to lethal means following a suicide-related emergency department visit.",[36,266],[268,350,351],"digital health","lethal means restriction","2026-06-01",{"date":354,"type":41},"2026-06-03",{"date":356,"type":22},"2026-06-15",{"date":358,"type":22},"2027-08-31",{"name":360,"class":48},"University of Texas Southwestern Medical Center",{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":23,"phases":369,"briefSummary":370,"conditions":371,"keywords":372,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":107},"100584241","implementing-a-secure-firearm-storage-program-in-illinois-health-centers-in-partnership-with-alliancechicago-and-the-illinois-primary-health-care-association-community-aspire-100584241","NCT06886776","Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Illinois Primary Health Care Association (COMMUNITY ASPIRE)","Inclusion Criteria:\n\nParent participants\n\n* Be a parent of a child ages 0-17 who has a well-visit at a participating health care clinic in the state of Illinois\n* Attend the child's well-visit\n\nHealth care personnel\n\n* Be employed at a participating health care clinic in the state of Illinois\n* Aged 18+ years\n\nExclusion Criteria:\n\n* None",{"count":368,"type":22},666,[25],"This randomized controlled trial will take place in up to 15 community health centers across the state of Illinois. Researchers will be studying S.A.F.E. Firearm, a program that aims to increase secure storage of firearms in homes with children. Specifically, S.A.F.E. Firearm includes a brief conversation between pediatric clinicians and parents about secure firearm storage and an offer of a free cable firearm lock within the well-child visit. Researchers will also study a package of strategies to help pediatric clinics incorporate this new practice. The strategies include training for clinic personnel and facilitation, or tailored problem-solving support.\n\nThe questions the study aims to answer are:\n\n* How effective is the package of strategies at helping pediatric clinics adopt this new practice?\n* How effective is the S.A.F.E. Firearm program at changing parents' and guardians' firearm storage behavior?\n\nSome parents and guardians will be invited to complete a brief survey after their visit about their experiences receiving S.A.F.E. Firearm. Some community health center personnel will also be invited to complete an interview about their experiences with S.A.F.E. Firearm and the package of strategies.",[36],[373,374,36,375,376],"Implementation science","Firearms","Pediatrics","Federally qualified health centers","2026-05-28",{"date":352,"type":41},{"date":380,"type":22},"2026-07-01",{"date":382,"type":22},"2028-12-31",{"name":384,"class":48},"Northwestern University",{"id":386,"slug":4,"hasResults":12,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":387,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":23,"phases":389,"briefSummary":63,"conditions":390,"keywords":391,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":392,"lastUpdatePostDateStruct":393,"startDateStruct":394,"completionDateStruct":395,"leadSponsor":396,"locationsCount":85},"100636169","Inclusion Criteria:\n\n* 18 years or older, capable of making decisions, and able to provide informed consent.\n* Major Depressive Disorder (MDD) according to DSM-5 criteria\n* Current depressive episode of moderate to severe intensity\n* Episode duration of at least two weeks\n* Baseline MADRS score ≥ 20\n* No treatment changes (including antidepressants) in the 4 weeks prior to the study\n* Abstain from psychedelics ≥14 days before dosing (D0) and during the 12-month follow-up\n\nExclusion criteria:\n\n* Major cardiac, hepatic, or renal disease; unstable cardiovascular conditions\n* Uncontrolled hypertension, QTc prolongation, arrhythmias, or valvular disease COPD or asthma\n* Severe obesity, uncontrolled diabetes, coagulopathy, thyroid disease, or glaucoma\n* Neurological risk (e.g., aneurysm, ↑ICP, epilepsy\u002Fseizures, severe disorders)\n* MAO deficiency or history of serotonin syndrome\n* Pregnant, breastfeeding, positive test, or no effective contraception\n* Secondary depression\n* Cluster B personality disorders (incl. borderline with ≥2 suicidal behaviors in past 12 months) or poor therapeutic rapport\n* Psychotic disorders, MDD with psychotic features, or first-degree family history of psychosis\u002Fbipolar disorder\n* Mania\u002Fhypomania (YMRS ≥8)\n* OCD, dissociative disorders, active PTSD, or decompensated eating disorders\n* Moderate-severe use disorder (past 6 months; except nicotine\u002Fcaffeine)\n* Lifetime ketamine, PCP, psychedelics, or MDMA use disorder\n* Current use of MAO inhibitors, unless discontinued at least 14 days prior to dosing\n* Psychedelic trial participation in past 12 months\n* Cognitive impairment affecting valid assessment",{"count":60,"type":22},[62],[31,65,66,67,36],[69,70,71,72,73,74,75,76],"2026-05-22",{"date":377,"type":41},{"date":80,"type":22},{"date":82,"type":22},{"name":84,"class":48},{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":406,"briefSummary":408,"conditions":409,"keywords":410,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":420,"locationsCount":4},"100628410","phase-4-self-hanging-patient-and-hyperbaric-oxygen-therapy--siphon-study-100628410","NCT07461272","Self-hangIng Patient and Hyperbaric Oxygen Therapy _ SIPHON Study","Self-hangIng Patient and Hyperbaric Oxygen Therapy - SIPHON Study \u002F Place de l'Oxygénothérapie Hyperbare Dans la Prise en Charge Des Tentatives de Pendaison","SIPHON","Inclusion Criteria:\n\nPatients who present, following an attempted hanging, neurological distress defined by the presence of one or more of the following criteria:\n\n* Glasgow score \\\u003C 13\u002F15\n* Confusional syndrome\n* Psychomotor agitation Who most of the time require optimal neuroprotection by sedation and invasive mechanical ventilation for the purpose of protecting the airways.\n* Patient aged over 18 years,\n* Suicide attempt by hanging without cardiocirculatory arrest,\n* Patient insured socially and able to understand the information provided\n\nExclusion Criteria:\n\n* Response time exceeded by \\> 6 hours from the hanging\n* Attempted hanging with immediate return to normal consciousness\n* Refusal of consent from the family or trusted person at the time of inclusion in the study,\n* Patients and\u002For families unable to understand the information provided",{"count":207,"type":22},[407],"PHASE4","During an attempted hanging, patients present severe neurological distress that can lead to major neuropsychiatric sequelae. These sequelae are notably due to significant cerebral edema related to hanging. Hyperbaric Oxygen therapy is known to reduce cerebral edema and improve cerebral perfusion. The main objective of the study is to evaluate in patients who have attempted hanging without presenting cardio-respiratory arrest, the effect of one Hyperbaric Oxygen therapy session in addition to standard intensive care management on a potential reduction in short-term neurological sequelae. Patients will benefit from either standard management or standard management associated with one Hyperbaric Oxygen therapy session",[36],[411,412,413,414],"Hanging","Neurological sequelae","Hyperbaric oxygen therapy","Intensive care","2026-05-20",{"date":392,"type":41},{"date":173,"type":22},{"date":419,"type":22},"2028-12",{"name":421,"class":48},"University Hospital, Lille",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":4,"eligibilityCriteria":428,"healthyVolunteers":16,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":429,"targetDuration":4,"studyType":23,"phases":431,"briefSummary":432,"conditions":433,"keywords":435,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":107},"100574426","romsi-mobile-health-intervention-to-enhance-suicide-prevention-by-reducing-stigma-and-increasing-literacy-100574426","NCT06759129","RomSi: Mobile Health Intervention to Enhance Suicide Prevention by Reducing Stigma and Increasing Literacy","RomSi (Rompiendo el Silencio) Mobile Health Intervention to Enhance Suicide Prevention by Reducing Stigma and Increasing Literacy: Protocol for a Cross-Over Randomized Controlled Trial","Inclusion Criteria:\n\n* Be 18 years old or older.\n* Have a cell phone with internet access during the intervention and follow-up periods.\n* Be able to speak, understand, and read in Spanish.\n\nExclusion Criteria:\n\n* Presence of high suicidal ideation (measured during screening, with a score above 20 on the total SIDAS scale or between 7 and 10 on the item assessing suicide attempts).\n* Presence of high social desirability bias (measured during screening, with a score of 14 or higher on the MC-SDS scale).\n* Altered mental status that impedes the ability to provide informed consent or assent (e.g., acute psychosis, intoxication, or mania).",{"count":430,"type":22},214,[25],"Suicide is one of the leading causes of death in Spain, representing a public health crisis that requires urgent and effective solutions. The stigma surrounding suicide prevents many at-risk individuals from seeking help, worsening the problem. Addressing this stigma is essential to implement more effective and accessible prevention strategies. This study aims to design and evaluate an innovative mobile health intervention to reduce stigma and encourage help-seeking behaviours in the general population. While the intervention targets the general population, two specific groups will access specialized and tailored content: individuals with low suicidal ideation and family members or close friends of people who have died by suicide. A daily assessment will collect real-time data and evaluate the intervention's impact. The study will employ a randomised controlled trial (RCT) with a crossover design, with participants randomly assigned to immediate or delayed use conditions. The intervention's effectiveness and usability will be assessed at four key points through quantitative analyses and qualitative interviews. We hypothesise that the intervention will improve suicide literacy, reduce suicide-related stigma, increase help-seeking behaviours, and demonstrate high usability and acceptability.",[434,36],"Suicidal Ideation and Behavior",[167,436,437,438,439],"Stigma","Suicide Literacy","Help Seeking","Randomized Controlled Trial","2026-05-07",{"date":442,"type":41},"2026-05-12",{"date":444,"type":41},"2025-10-15",{"date":446,"type":22},"2027-01",{"name":448,"class":48},"University of Valencia",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":454,"acronym":455,"eligibilityCriteria":456,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":343,"enrollmentInfo":457,"targetDuration":4,"studyType":23,"phases":458,"briefSummary":459,"conditions":460,"keywords":461,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":470,"lastUpdatePostDateStruct":471,"startDateStruct":473,"completionDateStruct":475,"leadSponsor":477,"locationsCount":107},"100609411","youth-empowerment-and-safety-intervention-100609411","NCT07214233","Youth Empowerment and Safety Intervention","Youth Empowerment and Safety Intervention for Systems-involved Sexual and Gender Minority Youth at Risk of Suicide","YES","Child Inclusion Criteria:\n\n* 12-17 years of age\n* Self-identify as a sexual or gender minority (SGM)\n* Involved in one or more system: juvenile justice, child welfare, and\u002For community-based mental health\n* Personal experience with self-injurious thoughts and behaviors (SITB)\n* English speaking\n* Willing and able to provide informed assent\n\nChild Exclusion Criteria:\n\n* Less than 12 or greater than 17 years of age (0-11 or 18 and over)\n* Do not self-identify as a sexual or gender minority (SGM)\n* Not involved in the juvenile justice, child welfare, and\u002For community-based mental health systems\n* No personal experience with self-injurious thoughts and behaviors (SITB)\n* Not English speaking\n* Unwilling and\u002For unable to provide informed assent\n\nCaregiver Inclusion Criteria:\n\n* 18-80 years of age\n* Primary Caregiver of youth who meet child inclusion criteria listed above\n* English speaking\n* Willing and able to provide informed consent\n\nCaregiver Exclusion Criteria:\n\n* Less than 18 or greater than 80 years of age (0-17 or 81 and over)\n* Not the Primary Caregiver of youth who meet child inclusion criteria listed above\n* Not English speaking\n* Unwilling and\u002For unable to provide informed consent",{"count":293,"type":22},[25],"This clinical trial will implement and evaluate the feasibility, acceptability, and initial impact of Peer Support Specialist (PSS) services for public system-involved sexual and gender minority (lesbian, gay, bisexual, queer and\u002For transgender) youth (SGMY) at risk of suicide.",[36,121],[462,463,464,465,466,467,468,469],"Self-injurious thoughts and behaviors (SITB)","Peer Support Specialist (PSS)","Behavioral health","adolescent","LGBTQ","Juvenile Justice","Foster Care","Crisis Response","2026-05-06",{"date":472,"type":41},"2026-05-08",{"date":474,"type":41},"2026-02-23",{"date":476,"type":22},"2027-11-30",{"name":478,"class":48},"Case Western Reserve University",{"id":480,"slug":481,"hasResults":12,"nctId":482,"briefTitle":483,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":485,"targetDuration":4,"studyType":23,"phases":487,"briefSummary":488,"conditions":489,"keywords":490,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":494,"lastUpdatePostDateStruct":495,"startDateStruct":496,"completionDateStruct":498,"leadSponsor":500,"locationsCount":107},"100631984","rapid-personalization-of-safety-plans-for-psychiatrically-hospitalized-veterans-at-high-risk-for-suicide-100631984","NCT07507786","Rapid Personalization of Safety Plans for Psychiatrically Hospitalized Veterans at High-Risk for Suicide","Inclusion Criteria:\n\nParticipants will be Veterans who are:\n\n* admitted to VABHS inpatient psychiatry for suicide risk\n* display sufficient English comprehension and cognitive capacity to understand the study and provide informed consent\n* have been medically cleared by attending physician\n\nExclusion Criteria:\n\nThe exclusion criteria for Veterans in this study are:\n\n* current psychosis\n* current mania\n* dementia or other significant cognitive impairment\n* being inaccessible and discharged from the unit less than 48 hours after being identified by study staff\n* prisoner status",{"count":486,"type":22},111,[25],"Veterans psychiatrically hospitalized face significantly elevated suicide risk, particularly in the three months post-discharge. While Safety Planning is a required component of discharge planning, many safety plans lack personalization thereby reducing their effectiveness. The proposed intervention, Personalized Safety Plans (PSP), will be developed for rapid delivery on acute inpatient psychiatry units. PSP is a single-session intervention followed by twice monthly brief, personalized coaching sessions during the three-month high-risk discharge period. PSP will be iteratively refined and finalized in a case series (N = 15) then evaluated in a pilot randomized controlled trial (N = 96) comparing PSP to Safety Plans as Usual among psychiatrically hospitalized Veterans. Overall, the study aims to: 1) iteratively refine PSP; 2) examine PSP's preliminary effectiveness in reducing suicide ideation and increasing adaptive coping; 3) identify barriers and facilitators to implementation; and 4) develop a fidelity measure to support future personalization monitoring.",[36],[491,492,493],"suicide prevention","safety planning intervention","implementation science","2026-05-05",{"date":470,"type":41},{"date":497,"type":22},"2026-10-01",{"date":499,"type":22},"2031-09-30",{"name":501,"class":282},"VA Office of Research and Development",{"id":503,"slug":504,"hasResults":12,"nctId":505,"briefTitle":506,"officialTitle":507,"acronym":508,"eligibilityCriteria":509,"healthyVolunteers":12,"sex":17,"minAge":510,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":513,"briefSummary":514,"conditions":515,"keywords":516,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":524,"startDateStruct":525,"completionDateStruct":527,"leadSponsor":529,"locationsCount":107},"100542133","brief-problem-solving-intervention-in-different-formats-for-the-prevention-of-suicide-in-adults-over-50-100542133","NCT06338904","Brief Problem-solving Intervention in Different Formats for the Prevention of Suicide in Adults Over 50","Efficacy of a Brief Poblem-solving Based Psychological Intervention Implemented in Different Formats for the Indicated Prevention of Suicide in Adults Over 50","SOLPROSU50+","Inclusion Criteria:\n\n* Be at least 50 years old\n* Reside in Galicia\n* Present suicidal ideation\n\nExclusion Criteria:\n\n* Present serious mental health or medical disorders\n* Have begun receiving psychological or psychopharmacological treatment in the previous two months or are participating in other suicide prevention research\n* Do not have an appropriate mobile device or sufficient fluency to communicate in Spanish, or have problems that make it impossible to participate\n* Plan to move in the next 18 months.","50 Years",{"count":512,"type":22},212,[25],"Suicide represents a personal tragedy and an enormous global public health problem. One of the most vulnerable groups is adults 50 years and older. Despite this stage of life is particularly amenable to the implementation of targeted suicide prevention strategies, we have few studies of the efficacy of psychological interventions, those that do exist have methodological limitations, and none were implemented in formats other than face-to-face, which limits their accessibility. There is a need for brief psychological interventions that can be administered in both face-to-face and remote formats, do not require long training periods, and are effective in different contexts: for example, problem-solving therapy. The main objective of this project is to evaluate the efficacy of a brief problem-solving psychological intervention for targeted suicide prevention in people aged 50 years and older, administered in face-to-face, conference call, and smartphone app formats. A randomized controlled trial will be performed. Participants will be recruited through healthcare centers in the Autonomous Community of Galicia (Spain). To be included, participants must: (a) be at least 50 years old, (b) reside in Galicia, and (c) present suicidal ideation. Subjects will be excluded if they: (a) present serious mental health or medical disorders; (b) have begun receiving psychological or psychopharmacological treatment in the previous two months or are participating in other suicide prevention research; (c) do not have an appropriate mobile device or sufficient fluency to communicate in Spanish, or have problems that make it impossible to participate; or (d) plan to move in the next 18 months. At pre-intervention information will be collected on sociodemographic, family, personal history, current suicide risk and other clinical variables. 212 participants will be randomly assigned to (1) a problem-solving-based psychological intervention delivered face-to-face (PSPI-FF; experimental group 1); (2) a problem-solving-based psychological intervention delivered via telephone conference call (PSPI-CC; experimental group 2); (3) a problem-solving-based psychological intervention delivered via a smartphone app (PSPI-A; experimental group 3); or (4) a usual care control group (UCCG). Participants in the experimental groups will complete the six sessions\u002Fmodules of the interventions. Finally, subjects in all groups will be evaluated at post-intervention and 3, 6 and 12-month follow-ups.",[36],[517,518,519,520,521,522],"randomized controlled trial","prevention","problem solving","conference call","App","Adults over 50","2026-04-28",{"date":494,"type":41},{"date":526,"type":41},"2023-09-01",{"date":528,"type":22},"2026-05-31",{"name":530,"class":48},"University of Santiago de Compostela",{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":535,"acronym":4,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":161,"maxAge":19,"enrollmentInfo":537,"targetDuration":4,"studyType":23,"phases":539,"briefSummary":540,"conditions":541,"keywords":543,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":523,"lastUpdatePostDateStruct":548,"startDateStruct":550,"completionDateStruct":552,"leadSponsor":554,"locationsCount":556},"100527699","preventing-suicidal-behavior-with-diverse-high-risk-youth-in-acute-care-settings-100527699","NCT06151158","Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings","Inclusion Criteria:\n\n* Suicide Risk During Acute Care Visit (At least one item in risk assessment is required; check all that apply): \\_\\_\\_ Chief complaint of suicide-related concern (via Medical Record\u002FOther), \\_\\_\\_ Active suicidal ideation endorsed in past 1 month on validated suicide screener, \\_\\_\\_ Suicidal behavior in the past 3 months on validated suicide screener, \\_\\_\\_ Clinician indicated SI in past month or SA in past 3 months.\n* Have access to a cellular phone with the ability to receive phone calls and text messages over the 12-month follow- up period\n* Adolescent must be verbally fluent and can communicate, understand, and read in either English or Spanish\n* Adolescent has been\u002Fwill be discharged from a higher level of care (i.e. inpatient, day hospital, partial hospitalization program (PHP), or residential treatment program) and back in the community within 4 weeks of their acute care visit. \\[Note: this criterion does not apply to all patients - select N\u002FA if this is the case.\n\nExclusion Criteria:\n\n* Significant cognitive or developmental delays that prevent understanding or using SPI+ or IPT-A-SCI (includes inability to communicate verbally)\n* Altered mental status (acute psychosis, intoxication, or mania)\n* Unable or unwilling to provide informed consent (adults), assent (minors), or permission (parents\u002Fcaregivers)\n* The services offered through the study are not in the best clinical interest of the patient (e.g., presenting problem requires a different level of care or treatment approach).",{"count":538,"type":22},1000,[25],"The study will compare the effectiveness of two relatively brief and scalable evidence-based interventions: the Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), a suicide-specific intervention that helps people prevent suicidal crises from escalating, and Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI), a psychotherapeutic crisis intervention treatment for suicidal adolescents that teaches youth skills to prevent suicidal crises and addresses interpersonal problems that lead to suicidal crises. The results will inform the future standard of care for youth at risk for suicide presenting in the ED setting. This project focuses on suicidal youth ages 12-24 in five ethnically and racially diverse urban areas: Philadelphia, Pennsylvania; Baltimore, Maryland; Chapel Hill, North Carolina; St. Petersburg, Florida; and Northern Manhattan\u002Flower Bronx\u002Feastern Queens communities in New York City, New York.",[30,542,36,167],"Suicide Ideation",[544,545,546,547,167],"Safety Planning Intervention","Ultra-Brief Crisis","Interpersonal Psychotherapy for Adolescents","Emergency Department",{"date":549,"type":41},"2026-05-04",{"date":551,"type":41},"2025-03-10",{"date":553,"type":22},"2028-10-14",{"name":555,"class":48},"Johns Hopkins University",6,{"id":558,"slug":559,"hasResults":12,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":23,"phases":566,"briefSummary":567,"conditions":568,"keywords":569,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":574,"lastUpdatePostDateStruct":575,"startDateStruct":577,"completionDateStruct":579,"leadSponsor":581,"locationsCount":107},"100543628","teem-gifts-a-gamified-mhealth-to-reduce-post-discharge-suicide-risk-100543628","NCT06358339","TEEM-GIFTS: A Gamified mHealth to Reduce Post-Discharge Suicide Risk","The Tailored Evidence-based Enhancements in Mental Health-Gamified and Individualized Follow-Up Treatment for Suicide (TEEM-GIFTS) : Implementing a Gamified mHealth Intervention to Reduce Post-Discharge Suicide Risk in Patients With Mental Disorders Using Multiphase Optimization Strategy (MOST)","Inclusion Criteria:\n\nFor patients\n\n* Being 18 years and above;\n* Being diagnosed with mental disorders;\n* Having received inpatient care for three days or more;\n* Living in Shenzhen and having no plan to leave Shenzhen in the following 12 months after discharge;\n* Being able to use apps or WeChat (WeChat mini program) on smart phones.\n\nFor lay health care supporters (LHSs)\n\n* Being 18 years and above;\n* Being without any diagnosis of mental disorder;\n* Being the lay health care supporter in the family;\n* Living in Shenzhen and having no plan to leave Shenzhen in the following 12 months after discharge;\n* Being able to use apps or WeChat (WeChat mini program) on smart phones.\n\nFor the clinic and community mental health service providers\n\n* Being 18 years and above;\n* Having practiced in mental health service at least for 12 months.\n\nExclusion criteria For patients\n\n* Refusing to provide written consent or be unable to provide written consent due to any cognitive problems.\n* Being discharged by the patient's or LHSs' demand against medical advice.\n* With no ID, no stable residence nor any source of income.\n\nFor For lay health care supporters (LHSs)\n\n* Refusing to provide written consent.\n\nFor the clinic and community mental health service providers\n\n* Refusing to provide written consent.",{"count":565,"type":22},640,[25],"Patients with mental disorders are at significantly higher risk of suicide after discharge compared to the general population and patients with other diseases. Currently, there is a lack of post-discharge community suicide risk management services in China. The research team's preliminary research suggests that mHealth interventions are well-accepted and feasible for reducing the suicide risk in patients with mental disorders. Furthermore, the inclusion of gamification elements can enhance treatment adherence and user engagement. However, determining the appropriate combination of gamification elements and evaluating the implementation effectiveness of gamified mHealth interventions for suicide risk are challenges in transforming these into regular community mental health services. This study will leverage gamification theory and community-based participatory research to design a gamified mHealth intervention model aimed at reducing suicide risk among discharged patients with mental disorders, and to develop a corresponding management strategy. Using the multi-phase optimization strategy (MOST), the study will identify the optimal combination of gamification elements to reduce suicide risk and increase the outpatient follow-up rate. Through an implementation science framework, the investigators will evaluate the process, outcomes, cost, and feasibility of this management strategy with the goal of reducing suicide risk among these patients. The findings from this study will provide a scientific basis for innovative suicide risk management models for discharged patients with mental disorders in China, thereby paving the way for the application of implementation science in mental health.",[36],[570,571,572,573,373],"Psychiatric patients","Post-discharge suicide","Gamification","Multiphase optimization strategy","2026-04-21",{"date":576,"type":41},"2026-04-24",{"date":578,"type":41},"2025-05-01",{"date":580,"type":22},"2027-12-31",{"name":582,"class":48},"Shenzhen Kangning Hospital",{"id":584,"slug":585,"hasResults":12,"nctId":586,"briefTitle":587,"officialTitle":588,"acronym":4,"eligibilityCriteria":589,"healthyVolunteers":12,"sex":17,"minAge":590,"maxAge":591,"enrollmentInfo":592,"targetDuration":594,"studyType":117,"phases":4,"briefSummary":595,"conditions":596,"keywords":597,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":600,"lastUpdatePostDateStruct":601,"startDateStruct":603,"completionDateStruct":605,"leadSponsor":607,"locationsCount":107},"100633192","investigation-on-suicide-risk-factors-of-patients-with-mood-disorders-100633192","NCT07523490","Investigation on Suicide Risk Factors of Patients With Mood Disorders","Investigation on Suicide Risk Factors of Patients With Mood Disorders in China","Inclusion Criteria:\n\n1. Age: 16 to 60 years old;\n2. seeing a doctor in a psychiatric clinic or a general hospital;\n3. Willing to cooperate in this research project;\n4. Sign the informed consent form (minors also need to obtain the informed consent signature of the guardian);\n5. Meet the diagnostic criteria of ICD-11 mood disorder.\n\nExclusion Criteria:\n\n1. unable to understand the contents of the questionnaire;\n2. Serious organic diseases such as cardiovascular disease, brain disease, liver disease and kidney disease, and weak body, which affect the respondents of the questionnaire;\n3. Other circumstances that make it impossible or unwilling to cooperate with the completion of the questionnaire.","16 Years","60 Years",{"count":593,"type":22},300,"3 Months","This study investigates the level and distribution of suicide risk and learned suicide ability of patients with mood disorders, investigates the related risk factors of suicide and suicide ability formation of patients with mood disorders from multiple dimensions (biological, psychological, social and clinical perspectives) and clarifies their importance, forms a list of suicide risk factors, and establishes a prediction model of learned suicide ability formation. Upon enrollment, participants will undergo comprehensive assessments including blood and urine sample collection and scale evaluation. The collection of scientific blood and urine is mainly used for the exploration of molecular mechanism of disease occurrence and development, the discovery and verification of biomarkers. Scale evaluation includes: Beck Scale for Suicide Ideation , Columbia Suicide Severity Rating Scale,, Hamilton Depression Rating Scale , Hamilton Anxiety Rating Scale, PHQ-9, GAD-7, Personal and Social Function Scale , Schihan Disability Scale , Emotional Adjustment Difficulty Scale , Acquired Capability for Suicide Scale, Interpersonal Needs Questionnaire , Ottawa Self-Injury Scale, Chinese version of Stress Perception Scale and Beck Hopelessness Scale . Follow-up was carried out for 3 months, including whether suicide\u002Fself-injury occurred, current status, and some baseline questionnaires (such as BSI-CV, GAD-7, PHQ-9, HAMD-17,HAMA, etc.).",[215,36],[215,268,598,599],"Biological Mechanism","prediction model","2026-04-18",{"date":602,"type":41},"2026-04-22",{"date":604,"type":41},"2025-12-31",{"date":606,"type":22},"2027-09-30",{"name":608,"class":48},"Tianjin Anding Hospital",{"id":610,"slug":611,"hasResults":12,"nctId":612,"briefTitle":613,"officialTitle":614,"acronym":4,"eligibilityCriteria":615,"healthyVolunteers":16,"sex":17,"minAge":161,"maxAge":343,"enrollmentInfo":616,"targetDuration":4,"studyType":23,"phases":618,"briefSummary":619,"conditions":620,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":621,"lastUpdatePostDateStruct":622,"startDateStruct":623,"completionDateStruct":625,"leadSponsor":627,"locationsCount":107},"100578223","nimh-clinical-pathway-in-rural-appalachian-school-based-health-clinics-100578223","NCT06808503","NIMH Clinical Pathway in Rural Appalachian School-based Health Clinics","Implementing the NIMH Clinical Pathway in Rural Appalachian School-based Health Clinics","Inclusion Criteria:\n\n* Youth who are receiving services at the school-based health centers to participate\n* Parents must be able to give legal consent for themselves and their children to participate\n* Youth and Parent must be English-speaking\n* Youth must also be able to give signed assent to participate\n* Youth must be cognitively and medically able to participate in study activities\n\nExclusion Criteria:\n\n* Youth in state custody will be excluded from study participation due to challenges related to obtaining legal consent.",{"count":617,"type":22},30,[25],"This study will adapt and evaluate an evidence-based suicide risk screening and follow-up program in two school-based health centers in West Virginia. The suicide screening program is titled the \"NIMH Clinical Pathway\" and provides tools and procedures for routinely screening adolescents for suicide risk, completing risk assessments, safety planning, lethal means restriction, follow-up referrals, and other disposition planning as appropriate.\n\nInvestigators aim to do the following:\n\n1. Gather formative data from providers, parents, and youth to inform ways to adapt and implement the NIMH Clinical Pathway so that it can be effectively implemented in rural, Appalachian School-Based Health Centers (SBHCs).\n2. Gather preliminary data regarding the feasibility, acceptability, and effectiveness of the adapted intervention.",[167,36],"2026-04-15",{"date":574,"type":41},{"date":624,"type":41},"2024-10-02",{"date":626,"type":22},"2027-05",{"name":628,"class":48},"West Virginia University",{"id":630,"slug":631,"hasResults":12,"nctId":632,"briefTitle":633,"officialTitle":634,"acronym":635,"eligibilityCriteria":636,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":637,"enrollmentInfo":638,"targetDuration":4,"studyType":23,"phases":639,"briefSummary":640,"conditions":641,"keywords":642,"overallStatus":168,"whyStopped":4,"lastUpdateSubmitDate":645,"lastUpdatePostDateStruct":646,"startDateStruct":648,"completionDateStruct":649,"leadSponsor":651,"locationsCount":107},"100619545","sleep-and-circadian-interventions-for-college-students-at-high-risk-of-suicide-100619545","NCT07346014","Sleep and Circadian Interventions for College Students at High Risk of Suicide","Triple Chronotherapy + Transdiagnostic Sleep and Circadian Intervention (TSC+) for Suicidal Young Adults","REST-UP","Inclusion Criteria:\n\n* Enrolled or planning to enroll in treatment at COSTAR Intensive Outpatient Program\n* English language fluency and literacy sufficient to engage in study protocol\n* Suicidal ideation or suicide attempt in past month\n* Clinically significant sleep disturbance, operationalized as Pittsburgh Sleep Quality Index global PSQI score \\>= 7, and\u002For delayed bedtimes (\\>midnight), and\u002For \\>2 hours in sleep timing variability\n\nExclusion Criteria:\n\n* Non-affective psychosis per electronic health record (EHR) review and\u002For baseline clinical assessment, or symptom severity or psychosocial functioning impairments that preclude participation\n* Contraindications for either sleep deprivation or bright light therapy (e.g., bipolar disorder; seizure disorder; photosensitizing medication)\n* Intellectual disability precluding comprehension of study procedures\n* Evidence of untreated obstructive sleep apnea and\u002For restless legs syndrome\n* Life-threatening medical condition requiring immediate treatment (such as cancer; end stage disease)\n* Pregnancy","25 Years",{"count":317,"type":22},[25],"The purpose of this study is to examine the extent to which delivering sleep and circadian focused interventions in addition to evidenced based psychiatric care for depression and suicide risk may contribute to decreasing suicide risk among high risk young adults. Investigators will evaluate three interventions targeting sleep in acutely suicidal college students enrolled in intensive outpatient treatment. Participants will be randomly assigned to one of three intervention groups:\n\n1. Triple Chronotherapy (TCT)+ Transdiagnostic Sleep and Circadian Intervention (TSC)\n2. Transdiagnostic Sleep and Circadian Intervention (TSC)\n3. Sleep Feedback (SF) Participants will be followed for 6 months with primary outcome domains of suicidal thoughts and behaviors and depression evaluated by blinded clinicians at short (Days 1-4 of intervention), medium (2 months) and long (6 month) term intervals.",[321,322,32,36],[643,268,644],"sleep disturbance","triple chronotherapy","2026-04-14",{"date":647,"type":41},"2026-04-16",{"date":173,"type":22},{"date":650,"type":22},"2029-03",{"name":335,"class":48},{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":657,"acronym":4,"eligibilityCriteria":658,"healthyVolunteers":12,"sex":17,"minAge":58,"maxAge":659,"enrollmentInfo":660,"targetDuration":4,"studyType":23,"phases":661,"briefSummary":663,"conditions":664,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":665,"lastUpdatePostDateStruct":666,"startDateStruct":667,"completionDateStruct":669,"leadSponsor":671,"locationsCount":49},"100522693","phase-1-feasibility-and-safety-of-ketamine-for-suicidal-patients-in-the-emergency-department-100522693","NCT06085937","Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department","Feasibility and Safety of Single Dose Ketamine for Acutely Suicidal Patients in the Emergency Department","Inclusion Criteria:\n\n* Acutely Suicidality (\"yes\" answer to any of items 4 or 5 on C-SSRS \"Suicidal Ideation\" category)\n* Require inpatient stabilization for SI or actions based on clinical observation and interview\n* Are accepted for psychiatric stabilization at the University of Kansas Medical Center's Strawberry Hill campus\n* Have a Glasgow Coma Score (GCS) of 15\n* Age 18-65\n\nExclusion Criteria:\n\n* Current or past history of psychosis\n* Current or recent (past 4 weeks) symptoms of mania\u002Fhypomania as defined by Young Mania Rating Scale (YRMS) score of 12 or greater\n* History of ketamine use disorder\n* History of liver transplant\n* Pregnancy or breastfeeding\n* Imprisonment or inability to consent\n* Positive urine drug screen or serum alcohol level\n* Hypertension (SBP \\> 160 or DBP \\> 100 before administration of ketamine)\n* Hypotension (SBP \\\u003C 90)\n* Presence of acute medical condition requiring admission to medical service\n* Allergy, intolerance, or previous adverse reaction to ketamine\n* Patient has 8+ lifetime ketamine exposures\n* The treating physician determines that the patient is not a good candidate for the study (e.g. medical condition\u002Fprocedure, medication that would contradindicate ketamine treatment)","65 Years",{"count":207,"type":22},[662],"PHASE1","There is currently no readily available pharmacologic intervention for suicidal ideation, a true psychiatric emergency, in the Emergency Department (ED). Investigators aim to trial low-dose, intravenous ketamine, a drug with well-established use in treatment-resistant depression, for patients who present to the ED with suicidal ideation.",[36,67,32],"2026-04-12",{"date":621,"type":41},{"date":668,"type":41},"2024-05-01",{"date":670,"type":22},"2027-04",{"name":672,"class":48},"Lindsay Maguire, MD"]